GUMDROP : JHMI 0858 Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer

Created by Marte, Jenn (NIH/NCI) [E], last modified by Channing Paller on Apr 14, 2012

Description:

Prostate cancer patients with the following high-risk features are eligible: clinical T2c, clinical or pathological T3 or T4 disease OR Gleason 8-10 disease OR PSA > 20ng/ml - no evidence of metastatic disease. The primary outcome measure is Maximum Tolerated Dose (MTD) of Sunitinib as defined by Dose Limiting Toxicity (DLT).

Link:

http://www.clinicaltrials.gov/ct2/show/NCT00631527

Site:

JHMI, MDA

Principal Investigator:

Song, Corn